Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis
Background: For patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, escalating adjuvant treatment improves outcomes. In high-risk patients, DESTINY-Breast05 found that trastuzumab deruxtecan (T-DXd) reduced the 3-year risk of recurrence compared with trastuzumab emtansine (T-...